Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Single-Cell proteomics discerns patient-specific subpopulations in pediatric B-cell acute lymphoblastic leukemia

Created on 29 Aug 2026

Authors

Jayousi, F., Kraus, F., Conrrero, A., Bush, J. W., Setiadi, A., Lange, P. F.

Abstract

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, representing ~30% of pediatric cancers and ~80-85% of pediatric ALL cases. Despite high remission rates, relapse remains a major challenge, often driven by therapy-resistant subpopulations, which are masked in bulk analysis, thus limiting our understanding of disease progression and optimal therapeutic intervention. Precision oncology enables proteome-level characterization of patient specific cancer samples and their subpopulations, essential for improving prognostic accuracy and individualized therapies. Single-cell proteomics by mass spectrometry (SCP-MS) enables quantification of hundreds to thousands of proteins at single cell level, uncovering cellular programs that may contribute to minimal residual disease (MRD) and relapse. Here, employing single-cell sorting of leukemic cells coupled with high-sensitivity SCP-MS, we profile individual leukemic blasts and normal immature B-cells from pediatric B-ALL bone marrow aspirates alongside age-matched controls. SCP-MS deconvoluted cellular heterogeneity and revealed subpopulations with variable leukemia-marker expression, highlighting its potential for early detection of relapse-prone phenotypes and personalized pediatric therapy.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 29 Aug 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement